Objectives: To compare the tigecycline activity profile against Acinetobacter spp. by Etest versus broth microdilution in isolates with high Etest MIC. Conclusions: Caution should be taken in interpreting Etest MICs of 2 mg/L for Acinetobacter spp. since strains with Etest MICs of 2-4 mg/L are susceptible when tested by microdilution. False non-susceptibility by Etest may exclude tigecycline as a therapeutic option in a field where multiresistance is the rule.
Introduction
A recent review reported a favourable clinical response for Acinetobacter spp. infections treated with tigecycline. 1 However, the outcome may be compromised in patients infected by isolates with a decreased susceptibility to tigecycline, as reported in one of the series included in the review. 1 As a new agent, surveillance of susceptibility to tigecycline is critical to detect changes in its activity profile, which depends on the medium used for susceptibility testing, testing methodology and on the MIC normal distribution relative to the breakpoint value. 2 This may be critical in an area where multiresistance is the rule as occurs in Acinetobacter spp. in Spain, which exhibits high resistance rates of 40% to carbapenems and .75% to quinolones, ceftazidime and gentamicin. 3 With respect to the medium used for susceptibility testing, differences in MIC values have been reported when determinations are performed using some commercial Mueller-Hinton media with elevated manganese concentrations. 4, 5 This fact may increase the reported difference in the MIC values obtained when using different testing methodologies, with higher MIC values (one to two dilutions) in determinations by Etest versus broth microdilution. 2 The aim of this study was to compare the activity profile of tigecycline against Acinetobacter spp. when determined by Etest versus broth microdilution in isolates exhibiting a high Etest MIC of tigecycline.
Materials and methods

Strains
Microbiology departments in five Spanish hospitals were contacted to prospectively obtain Acinetobacter spp. isolates with tigecycline MICs of 0.5 mg/L, determined by Etest, between January 2006 and July 2007. Isolates were frozen and sent to the study's central laboratory at Laboratories International for Microbiology Studies, International Health Management Associates Inc., for determination of tigecycline susceptibility by broth microdilution.
Susceptibility testing
In the hospitals, susceptibility to tigecycline was determined using commercially developed tigecycline Etest strips (AB Biodisk, Solna, Sweden) according to the manufacturer's instructions. 9 Briefly, an inoculum suspension with a turbidity equivalent to that of a 0.5 McFarland standard was prepared by suspending isolated colonies in 0.9% saline. A sterile cotton swab dipped into the suspension was used to evenly streak Mueller-Hinton agar (MHA) from bioMérieux (Marcy l'É toile, France) in four centres and MHA from Oxoid (Basingstoke, Hampshire, UK) in one centre. The Etest tigecycline gradient strip was applied to the agar surfaces and plates were incubated in ambient air at 358C for 18-20 h. The MIC was read where the growth inhibition ellipse intersected the MIC on the Etest gradient strip. Values read were rounded to the nearest upper double-dilution value.
At the central laboratory, susceptibility to tigecycline was determined by broth microdilution as directed by CLSI document M7-A7 10 using Mueller-Hinton broth (Remel, Lenexa, KS, USA).
The Spearman non-parametric correlation coefficient (R), with two-tailed significance to minimize the impact of outliers, was calculated between MIC values determined by Etest and broth microdilution.
Results
One hundred and forty-eight isolates with the requested Etest tigecycline MIC of 0.5 mg/L were collected. MHA bioMerieux was used for Etest MIC determination for 132 isolates (four centres) and MHA from Oxoid for 16 isolates (one centre). 
Discussion
An Etest has recently been developed for the susceptibility testing of tigecycline. 9 For most evaluated pathogens, Etest MICs tended to be one doubling-dilution higher than broth microdilution MICs and, in general, high correlation coefficients were obtained for Enterobacteriaceae with a negligible number of major errors (false non-susceptibility by Etest). 9 In Acinetobacter spp., due to the absence of CLSI breakpoints, false non-susceptibility by Etest was not explored. 9 The correlation between Etest and broth microdilution was high in a previous study by Pillar et al., with a correlation coefficient of 0.865, 2 a value much higher than the one obtained in the present study (0.238). This difference is probably due to the fact that the previous study was performed with non-selected strains, including a high number of strains with an Etest MIC 1 mg/L (susceptible following BSAC breakpoints), whereas in the present study the majority of strains (122/148; 82.4%) showed MICs of 2 mg/L (non-susceptible), as centres were asked to send isolates with MICs of 0.5 mg/L. In this sense, discrepancies between both methods occurred in intermediate (MIC values 1 -2 dilutions lower for broth microdilution) and resistant (MIC values 2 -3 dilutions lower for broth microdilution) isolates by Etest, while the same MIC value (all but one isolate) was obtained by both methods for tigecyclinesusceptible strains (MIC 0.5 -1 mg/L) by Etest. As the values of MIC determined by Etest increased, discrepancies between both methods increased, but always in the non-susceptibility Etest MIC range.
Considering the reference method of broth microdilution and applying the BSAC susceptibility breakpoint, high percentages of major errors (false non-susceptibility by Etest) were found since 93% of intermediate and 88.9% of strains resistant by Etest were susceptible when tested by broth microdilution. No major errors were found in the susceptible category, with all strains being susceptible by both methods.
During nationwide surveillance in Spain, tigecycline MIC values for the isolates tested were higher in one centre (University Hospital Marques de Valdecilla) than in others, probably due to the source of the MHA medium in that centre (Merck). 5 The hypothesis of MIC variation depending on the different compositions of Mueller-Hinton medium was corroborated 5 and higher resistance rates (as defined by the BSAC resistance breakpoint: .2 mg/L) were found when using Merck versus Difco or Oxoid medium in Acinetobacter spp. MIC determination by Etest, a fact attributed to the higher manganese levels in Merck's medium (630 ppm versus 2.5 ppm). 5 The medium used in the present study was from bioMerieux in four centres and, although this medium was not assessed in the previous study, 5 another group in Spain has also reported higher Etest MICs when using MHA medium from bioMerieux versus BBL or Biomedics. 4 Tigecycline MICs determined in MHA containing low manganese concentration may be more clinically relevant due to the low manganese concentrations in human serum (far from the high concentrations in Merck's MHA).
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The major finding of the present study was that discrepancies between Etest and microdilution were clustered in tigecycline-intermediate or -resistant strains (when MICs were determined by Etest). Caution should be taken in interpreting Etest MICs of 2 mg/L since strains with Etest MICs of 2 -4 mg/L are susceptible when tested by microdilution, and nonsusceptibility by broth microdilution is only clearly clustered in isolates with very high Etest MICs (8 mg/L). False nonsusceptibility by Etest may exclude tigecycline as a therapeutic option in a field where multiresistance is the rule. Further studies are needed to define the most adequate MHA medium (with adequate manganese concentration) in tigecycline susceptibility testing for Acinetobacter spp. with diffusion methods. 
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